CN102872005B - Application of the glycyrrhizin in treatment pneumonia medicine is prepared - Google Patents
Application of the glycyrrhizin in treatment pneumonia medicine is prepared Download PDFInfo
- Publication number
- CN102872005B CN102872005B CN201210231493.0A CN201210231493A CN102872005B CN 102872005 B CN102872005 B CN 102872005B CN 201210231493 A CN201210231493 A CN 201210231493A CN 102872005 B CN102872005 B CN 102872005B
- Authority
- CN
- China
- Prior art keywords
- glycyrrhizin
- aureus
- forms
- prepared
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to application of the glycyrrhizin in treatment pneumonia medicine is prepared, the protection test and mouse S. aureus L-forms pulmonary inflammation model damaged by rabbit erythrocyte hemolytic test, human squamous lung cancer (A549) confirms its therapeutic action infected S. aureus L-forms.Compared with antibiotic therapy, had using Radix Glycyrrhizae extract for treating and had no drug resistance, the characteristics of cure rate is high.
Description
Technical field
The present invention relates to application of the glycyrrhizin in treatment pneumonia medicine is prepared, belong to field of medicaments.
First, background technology
Glycyrrhizin (Liquiritigenin) is extracted in being the drying root and rhizome for belong to Radix Glycyrrhizae etc. from glycyrrhizic legume to be divided
A kind of flavone compound come is separated out, without significant antibacterial activity.Glycyrrhizin has extensive pharmacological action, with anti-
Scorching, antiviral, protecting liver and detoxication and improve the effect such as immunity, and naturally, efficiently, aboundresources and the resistance to the action of a drug it is not notable.In addition
Have no the report of Radix Glycyrrhizae extract for treating bacterial pneumonia both at home and abroad so far.
Bacterial pneumonia is by streptococcus pneumonia, haemophilus influenzae, staphylococcus aureus, micrococcus scarlatinae, army
The caused pulmonary infection of the infection such as group bacterium, disease case fatality rate in children, the elderly and immune deficient patients is high.In recent years
Come, a large amount of use of antibiotic causes Bacterial Drug Resistance of Patients to increase, and antibiotics research runs into bottleneck so that bacterial pneumonia
The situation without effective medical procedure faced awkwardness for the treatment of.At present on the one hand clinically with caused by staphylococcus aureus
The pneumonia state of an illness is more serious, especially pneumonia case fatality rate caused by methicillin-resistant staphylococcus aureus (MRSA) continue compared with
It is high.On the other hand usually using drug therapy staphylococcal pneumonias such as OXA and Cloxacillins, but due to MRSA
Appearance, can frequently result in that treatment is invalid, or even because the beta-lactam antibiotic of subinhibitory concentration promotes golden yellow grape
Pneumoniae pneumolysin is expressed, and increases treatment time, expense and the death rate.Therefore, new, safe pneumonia medicine is found to compel
In the eyebrows and eyelashes.Glycyrrhizin is the composition of China traditional Chinese medicine Radix Glycyrrhizae, and present invention research confirms glycyrrhizin element to bacterial pneumonia,
Especially pneumonia caused by drug-resistant S. aureus has preferable therapeutic effect.
2nd, the content of the invention
The molecular structure of glycyrrhizin is as follows：
Protection test and mouse gold that the present invention is damaged by rabbit erythrocyte hemolytic test, human squamous lung cancer (A549)
Portugal's bacterium pulmonary inflammation model confirms that it has the effect for the treatment of S. aureus L-forms infection.
3rd, embodiment
1. hemolytic test
The glycyrrhizin of staphylococcus aureus and various concentrations is co-cultured to stablizing growth period for 37 DEG C in TSB culture mediums.
Staphylococcus aureus in stationary phase has started to secrete hemolysin, through bacterium supernatant is collected by centrifugation.The bacterium supernatant of collection and rabbit
Red blood cell is diluted in PBS, is centrifuged after 37 DEG C of conditions are incubated 15min.Plus various concentrations glycyrrhizin system is with being not added with glycyrrhizin
The percentage of the erythrocytolysis of system is considered as Percent hemolysis (Hemolysis percentage).
It is not added with the Percent hemolysis such as table 1 below of alpha hemolysin after the glycyrrhizin of glycyrrhizin and addition various concentrations：
Inhibitory action of the glycyrrhizin of table 1. to alpha hemolysin hemolytic activity
2. the protection test of human squamous lung cancer (A549) damage
S. aureus L-forms NCTC 8325-4 cultivated in TSB culture mediums to5ml bacterial cultures is taken, centrifugation is simultaneously
It is resuspended in 10ml F12K culture mediums.A549 cells are in F12K culture mediums (adding 10% hyclone) in 37 DEG C, 5%
CO2After culture 24 hours, with 1.5 × 104Individual cells/well is laid in 96 porocyte culture plates, per the μ l of hole 100.After cell attachment,
100 μ l S. aureus L-forms suspensions are added, and add the glycyrrhizin of various concentrations, are placed in cell culture incubator in 37 DEG C, 5%CO2Training altogether
Support 8h.Live (green)/dead (red) reagent is added, after observation A549 cells under laser confocal microscope (LSCM)
State, the aobvious green of living cells, the aobvious red of dead cell.
As a result show, glycyrrhizin can protect human squamous lung cancer (A549) damage that S. aureus L-forms alpha hemolysin is mediated, should
Dose dependent is presented in effect.
3. the experimental therapeutic research of mouse S. aureus L-forms pneumonia
3.1 mouse S. aureus L-forms pulmonary inflammation models
C57BL/6J mouse (male, 18-22g) are after etherization, the μ l S. aureus L-forms suspension (S. aureus L-forms of intranasal administration 30
8325-4), mouse lies low until revival, sets up the model of mouse S. aureus L-forms pneumonia.Lethal test gives 4 × 108CFUs gold
Portugal bacterium, and histopathological examination gives 2 × 108CFUs S. aureus L-forms.
3.2 protective rates are tested
100,50 and 25mg/kg (100 μ l) glycyrrhizin is subcutaneously injected in 2h respectively after mouse inoculation S. aureus L-forms, the administration per 6h
Once.The physiological saline that control group gives 100 μ l, every group of 20 mouse are not administered.After Dosage Regimens Dosage, record respectively small
The death rate after mouse infection S. aureus L-forms 24h, 48h, 72h.
As a result show, after being handled through glycyrrhizin, significantly reduce the death rate (P ＜ 0.05) of mouse S. aureus L-forms pneumonia.Such as table
2.
Influence of the glycyrrhizin of table 2. to the mouse S. aureus L-forms pneumonia death rate
Claims (2)
1. application of the glycyrrhizin in treatment pneumonia medicine as caused by Staphylococcus aureus is prepared.
2. application according to claim 1, it is characterised in that the medicine includes pharmaceutically acceptable formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210231493.0A CN102872005B (en) | 2012-07-06 | 2012-07-06 | Application of the glycyrrhizin in treatment pneumonia medicine is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210231493.0A CN102872005B (en) | 2012-07-06 | 2012-07-06 | Application of the glycyrrhizin in treatment pneumonia medicine is prepared |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872005A CN102872005A (en) | 2013-01-16 |
| CN102872005B true CN102872005B (en) | 2017-07-14 |
Family
ID=47473679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210231493.0A Active CN102872005B (en) | 2012-07-06 | 2012-07-06 | Application of the glycyrrhizin in treatment pneumonia medicine is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872005B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4100018A4 (en) * | 2020-02-08 | 2024-03-13 | Lurong Zhang | Uses of glycyrrhetinic acid, glycyrrhizic acid for treatment of pneumonitis/pneumonia/pulmonary fibrosis |
-
2012
- 2012-07-06 CN CN201210231493.0A patent/CN102872005B/en active Active
Non-Patent Citations (3)
| Title |
|---|
| Luo Y, et al..Cytotoxic and antibacterial flavonoids from dragon"s blood of Dracaena cambodiana..《Planta medica》.2011,第77卷(第18期),2053-2056. * |
| 崔誉蓉等.4种甘草黄酮类化合物抗氧化构效关系研究.《时珍国医国药》.2010,第21卷(第12期),3041-3044. * |
| 甘草黄酮抗肺部炎症的实验研究;管燕;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20111215(第S1期);E057-485 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872005A (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1730015A (en) | Honey suckle extract and its preparing process and application | |
| CN101322810B (en) | Chinese traditional medicine composition for treating diabetes respiratory tract infection | |
| CN105770008A (en) | New application of folium syringae extract in preparing drugs for resisting drug-resistant bacterium infection diseases | |
| CN103690538B (en) | With the active Chinese medical extract of anti-poultry mycoplasma, Chinese medicine composition | |
| CN102872005B (en) | Application of the glycyrrhizin in treatment pneumonia medicine is prepared | |
| CN102872004B (en) | Application of the naringenin in treatment pneumonia medicine is prepared | |
| CN105412131A (en) | Application of verbascoside in preparation of pneumonia treatment drug | |
| CN103933350B (en) | Use of rhizoma bletillae ethyl acetate extract | |
| CN103191100A (en) | Application of puerarin in preparation of drug for treating pneumonia | |
| CN102058810A (en) | Lung-clearing asthma-relieving phlegm-reducing Chinese patent drug | |
| CN106474141A (en) | Osthole is combined application in preparation treatment pneumonia medicine for the baicalin | |
| CN102872003B (en) | Application of the apiolin in treatment pneumonia medicine is prepared | |
| CN104524547A (en) | Application of plectasin in inhibiting streptococcus agalactiae | |
| CN102379958B (en) | Chinese medicinal preparation for resisting bacteria, diminishing inflammation, eliminating phlegm and relieving cough and preparation method thereof | |
| CN102727509A (en) | Application of baicalin to preparation of medicament for treating pneumonia | |
| CN105193784A (en) | Application of ginkgetin in preparation of drugs for treating streptococcus suis infection | |
| CN101879174A (en) | Use of forsythiaside A in preparation of drugs for treating influenza | |
| CN111053764B (en) | Application of salvianolic acid A in preparation of medicine for treating methicillin-resistant staphylococcus aureus infectious pneumonia | |
| CN102429899A (en) | Application of baicalein to preparation of medicament for treating pneumonia | |
| CN102755311A (en) | Application of oroxylin A in preparing medicament for treating pneumonia | |
| CN103479659A (en) | Application of three kinds of oroxin in preparing drug for resisting staphylococcus aureus infection | |
| CN106265630A (en) | Amentoflavone application in research and development treatment pneumonia medicine | |
| CN102755313A (en) | Application of silibinin in preparation of medicament for treating pneumonia | |
| CN103191099B (en) | The application in anti-listeria infection medicine prepared by fisetin | |
| CN106667996B (en) | Morin is preparing the application in anti-streptococcus suis medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211224 Address after: 442100 No.2 Yingbin Avenue, Chengguan Town, Fang County, Shiyan City, Hubei Province Patentee after: HUBEI WUDANG ANIMAL PHARMACEUTICAL Co.,Ltd. Address before: 130012 No. 2699 Qianjin Street, Jilin, Changchun Patentee before: Jilin University |